Clinical Trial Update: Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 trial of mitomycin delivered via hyperthermic peritoneal perfusion for malignant ascites due to metastatic cancer, terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Ascites

Drugs mentioned

• Mitomycin (Mitomycin)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Metastatic Cancer | Phase 2 | Status: TERMINATED